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1. INTRODUCTION 
 
1.1. Definition of apoptosis 
 
The normal cell is confined to a fairly narrow range of function and structure by its genetic 
programs of metabolism, differentiation, and specialization; by constraints of neighboring cells; 
and by the availability of metabolic substrates. Generally, normal tissue homeostasis is 
characterized by a balance between proliferation and apoptosis. More severe physiologic stresses 
and some pathologic stimuli may bring about a number of physiologic and morphologic cellular 
adaptations, during which new but altered steady states are achieved, preserving the viability of 
the cell and modulating its function as it responds to such stimuli. A selective increase of 
proliferation leads to hyperplasia, or an increase in the sizes of individual cells, called 
hypertrophy. Conversely, atrophy is an adaptive response in which there is a decrease in the size 
and function of cells (1-4). 
 
Apoptosis is defined as an active physiological and genetically controlled process of cell suicide 
that carries an important function in the development and homeostasis of multicellular 
organisms. Since its discovery, apoptosis emerged as a molecular control point in the regulation 
of physiological processes, toxic insults and diseases by means of programmed cell death. 
Apoptosis occurs normally during development and aging and as a homeostatic mechanism to 
maintain cell populations in tissues. It also occurs as a defense mechanism such as in immune 
reactions or when cells are damaged by disease or noxious agents (5-7). It is a highly regulated 
and energy requiring process, controlled genetically and often elicited by endocrine signals (4-6). 
Apoptosis is the essential physiological mechanism for selective elimination of cells. It plays an 
integral part in a variety of biological events, including morphogenesis, the process of cell 
turnover and removal of harmful cells (8,9). 
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The process was recognized in 1972 by Kerr et al., by the distinctive morphologic appearance of 
membrane-bound fragments derived from cells, and named after the Greek designation for 
 
“falling off” (1,8,10,11). 
 
The historical development of the cell death concept is reviewed, with special attention to the 
origin of the terms necrosis, coagulation necrosis, autolysis, physiological cell death, 
programmed cell death, chromatolysis (the first name of apoptosis in 1914), karyorrhexis, 
karyolysis, and cell suicide, of which there are three forms: by lysosomes, by free radicals, and 
by a genetic mechanism (apoptosis) (1,11,12,13). 
 
Direct environmental stress and injury produce cell death by both necrosis and apoptosis (14). 
Although both necrosis and apoptosis result in cell death, they differ in several morphological 
and cellular regulatory features. Whereas necrosis is always a pathologic process, apoptosis 
serves many normal functions and is not necessarily associated with cell injury. Necrosis is 
characterized by the rapid loss of cellular homeostasis, rapid swelling as a result of the 
accumulation of water and electrolytes, early plasma membrane rupture, and the disruption of 
cellular organelles (Figure 1) (15). It induces an inflammatory response (4-6). Apoptotic cells 
break up into fragments, called apoptotic bodies, which contain portions of the cytoplasm and 
nucleus (10). 
 
Although we emphasize the distinctions between necrosis and apoptosis, there may be some 
overlaps and common mechanisms between these two pathways. In addition, at least some types 
of stimuli may induce either apoptosis or necrosis, depending on the intensity and duration of the 
stimulus, the rapidity of the death process, and the biochemical derangements induced in the 
injured cell (3,16). When damage to membranes is severe, or absent sources of cell energy, 
lysosomal enzymes enter the cytoplasm and digest the cell, and cellular contents leak out, 
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resulting in necrosis (3). Some noxious stimuli, especially those that damage deoxyribonucleic 
acid (DNA), induce another type of death, apoptosis, which is characterized by nuclear 
dissolution without complete loss of membrane integrity. 
 
Sloviter suggested that perhaps the terms necrosis and apoptosis should be redefined as “passive 
cell death” and “active cell death” (5,7). The mechanism whereby apoptosis is induced has 
recently gained attention as a possible treatment for a variety of diseases including excessive cell 
proliferation (17). However, apoptosis is also involved in a wide range of pathologic conditions, 
including acute neurological injuries, neurodegenerative diseases, cardiovascular diseases, 
immunological diseases, acquired immune deficiency syndrome (AIDS), and cancer (18). The 
process of apoptosis is controlled by various signals originating extracellularly or intracellularly. 
In living cells, apoptotic mitochondrial changes are predominantly prevented by anti-apoptotic 
Bcl-2 members (9,19). The duration of apoptosis is estimated to be from 12 to 24 hours, but in 
cell culture visible morphologic changes are accomplished in less than two hours (13). The 
process is under genetic control and can be initiated by an internal clock, or by extracellular 
agents such as hormones, cytokines, killer cells, and a variety of chemical, physical, and viral 
agents (6,12,19). 
 
 
1.1.1. Morphologic and biochemical changes in apoptosis 
 
Apoptosis is an active, genetically controlled type of cell death with distinct morphologic and 
biochemical features (20,21). It involves cell suicide in response to intrinsic signals 
(mitochondrial pathway) or extrinsic stimuli (death receptor pathway) in order to maintain 
homeostasis of the organism. Because apoptotic and necrotic stimuli both lead to mitochondrial 
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damage, this organelle appears to be a point of convergence of the pathways that mediate these 
morphologically distinct forms of cell death (1,6,19,22). 
 
The cell death process is executed in an organized fashion reflecting the presence of well-
preserved molecular pathways (23). The process may be divided into an initiation phase, during 
which some caspases become catalytically active, and an execution phase, during which other 
caspases trigger the degradation of critical cellular components. The initiation phase occurs from 
two pathways: intrinsic (mitochondrial) and extrinsic (death-receptor initiated) pathway 
(1,6,24). 
 
The basic morphological characteristics of apoptotic cells and apoptotic bodies have been 
described on the basis of classic light microscopy of histologic hematoxylin-eosin (HE) stained 
slides. The apoptotic cell appears as a round or oval mass with dark eosinophilic cytoplasm and 
dense purple nuclear chromatin fragments (1,13,25). Morphology is characterized by: 
 
- Cell shrinkage: the cell is smaller in size; the cytoplasm is dense, dark red; and the 
organelles, though relatively normal, are more tightly packed. 
 
- Chromatin condensation: the chromatin aggregates peripherally, under the nuclear 
membrane, into dense masses of various shapes and sizes. The biochemical hallmark of 
apoptosis is degradation of DNA into nuclear fragments (20). The nucleus itself may 
break up, producing two or more fragments (karyorrhexis) (1,23). 
 
- Formation of cytoplasmic blebs and apoptotic bodies: the apoptotic cell first shows 
extensive surface blebbing, then undergoes fragmentation into membrane-bound 
apoptotic bodies composed of cytoplasm and tightly packed organelles, with or without 
nuclear fragments, surrounded by light, “hollow space” (halo) (25). 
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- Phagocytosis of apoptotic cells or cell bodies, usually by macrophages: the apoptotic 
bodies are rapidly ingested by phagocytes and degraded by the phagocyte’s lysosomal 
enzymes (Figure 1) (1,10,15,16,23,24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic illustration of morphologic changes in cell injury culminating in necrosis 
or apoptosis adopted from Robins and Cotran (15) 
 
 
 
 
Plasma membranes are thought to remain intact during apoptosis, until the last stages, when they 
 
become permeable to normally retained solutes (10,13,25). 
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Quantification of apoptosis should include enough microscopic fields and identification of the 
cell type undergoing apoptosis (13). Belicza showed that during more than 25 years of research 
into apoptosis, the Zagreb Group for the Study of Apoptosis (Apoptosis Section, Department of 
Basic Medical Sciences, Academy of Medical Sciences of Croatia) has found it possible to 
determine the number of apoptotic cells and apoptotic bodies (apoptotic index) in daily routine 
on classic HE stained histologic slides by counting in 10 large fields under light microscope, 
following the methodology of mitotic index determination (25). 
 
 
1.1.2. Control and regulation of apoptosis 
 
Apoptosis is now possible to prove in several ways: a) microscopic cell changes; b) on the basis 
of DNA fragmentation; c) proof of caspase; d) changes in the cell membrane; e) mitochondrial 
tests (5,7,12). 
 
The apoptotic process is regulated by specific activation of a family of intracellular cysteine 
proteases known as caspases (cysteine aspartyl-specific proteases) inducible by various cellular 
and external stimuli. Two regulatory pathways are recognized. The intrinsic pathway 
(mitochondria pathway or type I) is regulated by apoptosis promoter proteins (such as Bax or 
Bcl2) and involves specific caspases (especially caspase 9) along with the participation of 
mitochondria. The extrinsic pathway (trans-membrane pathway or type II) is regulated by 
proteins such as Fas, the tumor-necrosis factor receptor (TNF-R) family proteins and involves 
specific caspases (especially caspase 8) connecting ligand binding at the cell surface to apoptosis 
induction (1,3,21,26). 
 
The Bcl-2 family is the best characterized protein family involved in the regulation of apoptotic 
cell death, consisting of anti-apoptotic and pro-apoptotic members. The Bcl-2 gene family 
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consists of >15 members (14,18). Krijnen et al. studied the expression of two such regulatory 
proteins, Bcl-2 and Bax, in the hearts of patients who died of acute myocardial infarction 
(3,5,18). No Bcl-2 was found in the infarcted area itself (5). The anti-apoptotic members of this 
family, such as Bcl-2 and Bcl-XL, prevent apoptosis either by sequestering proforms of death-
driving cysteine proteases called caspases (a complex called the apoptosome) or by preventing 
the release of mitochondrial apoptogenic factors such as cytochrome c and apoptosis-inducing 
factor (AIF) into the cytoplasm. After entering the cytoplasm, cytochrome c and AIF directly 
activate caspases that cleave a set of cellular proteins to cause apoptotic changes. In contrast, 
pro-apoptotic members of this family, such as Bax and Bak, trigger the release of caspases from 
death antagonists via heterodimerization and also by inducing the release of mitochondrial 
apoptogenic factors into the cytoplasm via acting on mitochondrial permeability transition pore, 
thereby leading to caspase activation (8,9,14). 
 
Bcl-2 is a mitochondrial membrane protein which protects against a wide variety of stimuli 
which induce apoptosis. Bcl-2 family members can homodimerise or heterodimerise with other 
family members, such as pro-apoptotic proteins Bax and the balance of expression between 
family members can predispose or protect against apoptosis. Bcl-2 and Bax are homologous 
proteins that have opposing effects on cell life and death, with Bcl-2 serving to prolong cell 
survival and Bax acting as an accelerator of apoptosis. Bax is a member of Bcl-2 family and 
when overexpressed, accelerates apoptosis (5,9,27). 
 
In recent years, it has been well established that Bcl-2 prevents most forms of apoptotic cell 
death as well as certain forms of necrotic cell death. A large number of Bcl-2-related proteins 
have been isolated and divided into three categories: 
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1. Anti-apoptotic members such as Bcl-2, Bcl-xL, Bcl-w, Mcl-1, A1 (B£-1) and Boo, all of 
which exert anti-cell death activity and share sequence homology, particularly within four 
regions, Bcl-2 homology (BH) 1 through BH4, although some members lack an apparent BH4 
domain. 
 
2. Pro-apoptotic members such as Bax, Bak, Bad, Mtd (Bok), Diva, which share sequence 
homology in BH1, BH2 and BH3 but not in BH4, although significant homology at BH4 has 
been noticed in some members. 
 
3. `BH3-only proteins', the pro-apoptotic proteins which include Bik, Bid, Bim, Hrk (DP5), 
Blk and Bnip3, Bnip3L, and share sequence homology only in BH3 (9). 
 
Proteins of the Bcl-2 family together with mitochondria, cytochrome c, and caspases, have 
among others been identified as essential components of the intracellular apoptotic signaling 
pathways (14,18). 
 
 
p53 protein accumulates in cells when DNA is damaged, and it arrests the cell cycle to allow 
time for repair. However, if the damage is too great to be repaired successfully, p53 triggers 
apoptosis (24). p53 has been called a “cellular gatekeeper” by Levine in 1997, or “the guardian 
of the genome” by Lane in 1992, because of its central role in coordinating the cellular responses 
to a broad range of cellular stress factors (28). The p53 protein is expressed by all normal cells, 
but the half-life of the normal protein is so short (6 to 30 minutes) that it does not accumulate in 
levels high enough to be detected by standard immunohistochemical techniques (29-31). By 
contrast, mutant p53 protein has an extended half-life, accumulates, and is readily detectable in 
the cell nucleus. Alterations are extremely common in human cancer (32). Inactivation of the p53 
tumor suppressor gene occurs in over half of all human tumors, implying that loss of this gene 
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represents a fundamentally important step in the pathogenesis of cancer (1,27). p53-related 
apoptosis is one of the regulatory mechanisms of vein wall homeostasis. During varicose vein 
development, its activation occurs in the early stages of the disease (30,33). 
 
 
Caspases are cysteine proteases divided functionally into two groups: initiator (caspase 8, 
caspase 9) and executioner (caspase 3, caspase 6, caspase 7), depending on the order in which 
they are activated during apoptosis. In general, caspases form a key step in the process of 
apoptosis and serve as the central executioners of apoptosis (3,5,19,34). Although there are at 
least 14 caspases in humans, only a subset of these enzymes is detectably proteolytically 
activated by various distinct death stimuli in different cell types (35). Execution phase of 
apoptosis is mediated by a caspase 3 dependent pathway (10). Caspases are crucial mediators of 
programmed cell death (apoptosis) (6,35). 
 
The significance of apoptosis has mostly been studied using the TUNEL assay (terminal 
deoxynucleotidyl transferase (TdT)-labeled dUTP nick labeling), a method described by Gavrieli 
et al. The TUNEL method detects DNA strand breaks in tissue sections and allows quantification 
and location of apoptotic cells by light microscopy, but is insufficient in distinguishing the 
different types of cell death (7,13,14,20). 
 
 
1.2. Apoptosis in vessels 
 
The formation of new blood vessels is an essential part of many physiological and pathological 
processes including embryogenesis, wound healing, formation of blood supply to tumors or 
ischemic tissue. Remodeling of a vessel describes an increase and decrease in its lumen size 
accompanied by changes in vessel wall area and components. One of the factors influencing 
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vascular wall development and remodeling is programmed cell death, which regulates tissue 
mass and its architecture. A number of studies have demonstrated programmed cell death in 
vessels that remodel postnatally, as a result of a balance between apoptosis and cell proliferation 
(11,30,36). 
 
Vascular smooth muscle cells can perform both contractile and synthetic functions, which are 
associated with and characterized by changes in morphology, proliferation and migration rates, 
and the expression of different marker proteins. Because of the diversity among smooth muscle 
cells, blood vessels attain the flexibility that is necessary to perform efficiently under different 
physiological and pathological conditions (11,36,37). Apoptosis has been detected in 
atherosclerotic lesions of native coronary arteries, specimens from vein grafts, especially in 
restenotic lesions with high apoptotic index near 70%, varicose veins and other changes 
(2,14,38). Cell death occurs in both physiological and pathological contexts in the cardiovascular 
system. Physiological cell death is responsible for the sculpting and remodeling of the heart and 
blood vessels in response to the changing requirements of the tissues they supply (11,39). 
 
 
1.2.1. Apoptosis in atherosclerotic disease 
 
Atherosclerosis, the principle cause of heart attack, stroke and gangrene of the extremities, is 
responsible for more than a half of all mortality in Europe. The lesions result from an excessive, 
inflammatory-fibroproliferative response to various forms of insult to the endothelium and 
smooth muscle of the artery wall (40). Observations that cell death occurs in atherosclerosis have 
already been made by Virchow in 1858 (11). 
 
The middle layer of the healthy vessel wall, the tunica media, contains an abundant population of 
vascular smooth muscle cells. During atherosclerosis, lipoproteins and cells accumulate in the 
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tunica intima, which is the innermost layer that separates the media from the lumen (41). Studies 
in human renal, coronary and carotid arteries have shown increased apoptosis and increased 
numbers of intrinsic pathway promoters including the apoptotic promoter Bax (26). 
Atherosclerotic lesions are characterized by regions displaying an excessive proliferation of the 
intimal tissue alterating with tissue death (4). As the main cellular components of the blood 
vessels, endothelial cells (EC) and smooth muscle cells (SMC) play central roles in vascular 
biology and pathology. Vascular endothelial cells are continuously exposed to a range of 
hemodynamic forces, which have a great impact on their cellular structure and function. The 
apoptotic death of smooth muscle cells could play a significant role in the aortic and plaque 
rupture. Massive induction of EC apoptosis in manipulated arteries can induce the formation of 
thrombus with appearances similar to eroded vessels, which suggests that EC apoptosis may 
trigger thrombosis (2,10,11,38,39). 
 
It has been suggested that apoptosis contributes to the pathogenesis of atherosclerosis and to the 
instable plaque syndrome. Variations in blood flow play an important role in vessel growth or 
regression, and in the development of atherosclerosis (11,42). Bartels et al. showed high rates of 
SMC apoptosis in atherosclerotic lesions (42). Thus, loss of vascular smooth muscle cells 
(VSMC) by apoptosis would be expected to weaken the cap and predispose to rupture (11,39). 
 
Apoptosis has been observed less consistently in primary atherosclerotic plaque than in 
restenotic specimens. It has been found more frequently in restenosis than primary human 
vascular lesions, because restenotic lesions are more proliferative than primary lesions (43). 
 
Kovačević et al. in their study concluded that medical treatment which reduces inflammation and 
proteolysis in the aortic wall, and supports the VSMC recovery, is required to reduce the 
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aneurysm expansion and prevent rupture (38). Mallat et al. believe that strategies aimed at the 
inhibition of apoptosis may limit plaque erosion, thrombosis and progression (11). 
 
 
1.2.2. Apoptosis in veins 
 
SMCs, being a part of the local contractile units, are responsible for active venous tone 
maintenance (11,30,31). Autologous vein grafts are a common procedure for vascular 
reconstruction, but their patency rate is limited due to neointimal hyperplasia (NIH) that 
develops rapidly in veins subject to arterial blood pressure. The principal cause of graft failure is 
obliterative stenosis of the vessel because of proliferative thickening of the intima. A hallmark of 
neointimal lesions is SMC migration/proliferation and extracellular matrix deposition (44). Mayr 
et al. demonstrated that one of the initial events after grafting veins to arteries was SMC 
apoptosis followed by mononuclear cell infiltration and SMC proliferation (31,44-47). 
 
Filis et al. evaluated a series of mediators regulating the apoptotic pathway and cell proliferation 
in human surgical specimens of varicose veins and healthy veins of the lower limbs. They 
showed that apoptotic deregulation is present in primary varicose veins. Bax, caspase 3, Bcl-xs 
and Ki-67 expressions were increased in great saphenous veins of patients suffering primary 
varicose veins. They could not detect Bcl-2 expression in their specimens (48). Increased 
apoptotic activity within the media of varicose veins has been shown by Bujan et al. The walls of 
healthy, control vein specimens acquired a more collagenous and papillomatous appearance with 
age (49). 
 
In their study of apoptosis in primary varicose veins, Urbanek et al. documented an increase in 
SMC diameter, the presence of intracellular vacuoles, disruption of the fibers of the elastic 
network containing hypertrophic secretory SMCs, and extracellular matrix accumulation 
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(15,30,31,46). Simovart et al. found a trend of the number of apoptotic cells to increase in the 
walls of varicose veins along with the advancing age. The advancing age can itself be a factor 
that sensitizes cells to apoptosis (50,51). 
 
 
1.3. Chronic renal insufficiency: etiology and pathogenesis 
 
Acute kidney failure is a sudden loss of kidney function. Kidney damage maybe reversible if it is 
caused by serious injury from shock, trauma, an accident, medication, or obstruction. 
 
Chronic renal disease is a progressive loss in renal function over a period of months or years. In 
the United States, the most recent data suggest that 27 million individuals have chronic kidney 
disease, representing nearly one in every seven adults and a 30% increase over the past decade. It 
rises dramatically with age, and is also associated with obesity and diabetes. Many patients with 
impending renal failure are regularly seeing their primary physician or a nephrologist. Symptoms 
may include: poor appetite, vomiting, bone pain, headache, insomnia, itching, dry skin, fatigue 
with light activity, muscle cramps, high urine output or no urine output, recurrent urinary tract 
infections, pale skin, bad breath, metallic taste in mouth, irritability, tissue swelling. 
Interventions, such as maintaining optimal blood pressure control, may delay or halt the 
development of progressive renal disease (52-57). 
 
Therapy for the end-stage renal disease has evolved in the past 50 years so that three major 
treatments are available:1) hemodialysis, typically provided in a dialysis center but also 
performed at home; 2) automated peritoneal dialysis, usually chronic ambulatory peritoneal 
dialysis or chronic cycling peritoneal dialysis; and 3) renal transplantation from a living-related, 
living-unrelated, or cadaver donor (53,58). 
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1.4. Apoptosis and End-Stage Renal Disease 
 
Apoptosis promotes the loss of renal epithelial cells that characterizes acute and chronic kidney 
diseases. Examples are podocytopenia and tubular cell loss in acute kidney injury and chronic 
tubular atrophy (3). Enhanced apoptosis is characteristic for chronic kidney disease (59). 
 
End-Stage Renal Disease (ESRD) patients under hemodialysis (HD) are characterized by a 
chronic inflammatory state that includes aberrant and chronic production of inflammatory 
cytokines such as interleukin (IL)-6 (60). They are more likely to display spontaneous apoptosis 
(61,62). 
 
It has been suggested that the systemic presence of uremic proteins and the dialysis procedure 
itself may promote immune cell activation and hence inflammation (60,63,64). The mononuclear 
cell recognizes the hemodialysis membrane as a foreign element and thus, in accordance with the 
immunologic concept, activates itself to produce a specific cellular response. These cells are 
more liable to die by apoptosis. This apoptosis is directly related to the degree of 
biocompatibility of the dialysis membrane (61,62). In hemodialysis patients, it is unclear whether 
increased apoptosis of neutrophils is due to uremia or HD itself. Previous studies have suggested 
that even though HD generates pro-apoptotic factors, the procedure causes only a transient 
sequestration of potentially apoptotic neutrophils (64,65). 
 
 
1.5. Venous anatomy in the upper limb 
 
Veins physiology is more complex than arterial physiology. Veins differ from arteries in a 
number of ways: have thinner walls, are collapsible, contain valves that are oriented to ensure 
unidirectional flow. Veins have a larger diameter than that of their accompanying arteries and in 
the periphery are usually duplicated (57,66-68). 
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- Superficial veins 
 
The major superficial veins of the upper limb are the cephalic and basilic veins. As their name 
suggests, they are located within the subcutaneous tissue of the upper limb. 
 
The basilic vein originates from the dorsal venous network of the hand. It ascends the medial 
aspect of the upper limb. At the border of the teres major, the vein moves deep into the arm. 
Here, it combines with the brachial veins to form the axillary vein (Figure 2) (69). 
 
The cephalic vein arises from the dorsal venous network of the hand. It ascends the antero-lateral 
aspect of the upper limb, passing anteriorly at the elbow. At the shoulder, the cephalic vein 
travels between the deltoid and pectoralis major muscles (known as the deltopectoral groove), 
and enters the axilla region via the clavipectoral triangle. Within the axilla, the cephalic vein 
terminates by joining the axillary vein. 
 
At the elbow, the cephalic and basilic veins are connected by the median cubital vein (66-69). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Venous anatomy in the upper limb adopted from Shenoy (69) 
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- Deep veins 
 
The deep veins of the upper limb are situated underneath the deep fascia. They are paired veins 
that accompany and lie on either side of an artery. The brachial veins are the largest in size, and 
are situated on either side of the brachial artery. The pulsations of the brachial artery aid the 
venous return. Veins that are structured in this way are known as venae comitantes (67-73). 
 
Perforating veins run between the deep and superficial veins of the upper limb, connecting the 
two systems. Lower extremity veins differ from upper extremity veins, but also deep conduit 
veins differ from superficial veins in terms of anatomy, histology and function. 
 
Unlike calf veins, superficial forearm veins have an important role in thermoregulation 
(22,57,66,68,69,71,72,74,75). 
 
 
1.6. Layers of the vein wall 
 
The tunica intima is the inner layer of the vein and consists of a smooth, elastic endothelial 
lining. This surface has several different functions, one of which is its immunological properties 
that cause it to recognize foreign bodies within the vein. Injury to the endothelial lining can be 
mechanical, chemical or bacterial in nature. 
 
The tunica media of the vein wall consists of muscle and elastic tissue. This layer is thick and 
comprises the bulk of the vein. The smooth muscle cells and the associated extracellular matrix 
is the major structural component of the vessel wall in both arteries and veins. They exist in the 
media of arteries and veins, bounded by the internal and external elastic laminae. The outer 
media is described as circular and the inner as longitudinal, reflecting the orientation of the cells 
(74). The nerve fibers that control vasoconstriction, vasodilation and that maintain muscle tone 
are also found in tunica media. 
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The adventitia is the outer layer of the vein and consists of connective tissue. It provides support 
and protection for the vein. 
 
As the main cellular components of the blood vessels, ECs and SMCs play central roles in 
vascular biology and pathology (74,76). 
 
 
1.7. Venipuncture 
 
Venipuncture is the practice of obtained intravenous access. This can be for intravenous therapy, 
or obtaining a blood sample. The main location for venipuncture is the median cubital vein. This 
is a superficial vein that is situated anteriorly at the elbow. It is commonly used due to its 
accessible and superficial position. Intravenous sites on the extremities should be chosen from 
most distal to proximal. Venipuncture must be avoided in areas of flexion and extension (56,77-
79). Puncture of a vein will leave a scar. When a fistula is created, such scars interfere with 
harmonious dilation and remodeling, cause turbulent flow, and predispose to stenosis (80-84). 
The veins of both arms, not only of the dominant arm, should remain untouched. It is important 
to instruct the patient in time and to motivate them that forearm veins are preserved (78,85). For 
venipuncture, the veins of the dorsum of the hand should be used as an alternative. Venipuncture 
complications may render veins potentially available for vascular access unsuitable for 
construction of a primary fistula (55,80,81). Because the patient who requires renal hemodialysis 
has usually undergone a period of intensive treatment requiring prolonged intravenous therapy, 
the readily available sites soon become consumed. Therefore, the selection of the site and type of 
shunt or fistula to be performed is equally important as the technique of performing the operation 
(55,56,57,77,80,81,82,86). 
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1.8. Hemodialysis 
 
Hemodialysis is a life-saving treatment used to clean the blood of waste products and extra 
fluids. Chronic renal failure is a common illness with life-threatening manifestations that can be 
controlled with the use of hemodialysis (78,82,87). 
 
The first clinical report of hemodialysis is credited to Wilhelm Kolph. Using hemodialysis, he 
managed a patient with acute renal failure in 1944. The dialysis was effective in controlling 
azotemia. His patient died after 12 hemodialysis treatments (53,57,66,88). 
 
The number of patients with the End-Stage Renal Disease (ESRD) who require maintenance 
hemodialysis has risen sharply in the past two decades. It is approximately 300.000 in the United 
States and exceeds 25.000 in Turkey (89,90). Large clinical studies have shown that the 
mortality rate of patients undergoing HD is markedly elevated (60). These rates are striking: for 
example, a 30-year-old person with ESRD has the life expectancy of that of an 80-year-old 
person with the normal renal function (91). 
 
Access to the blood contained within the vascular system was the dream of the ancient physician. 
Techniques of bleeding by incision, leeches and others were recognized as having therapeutic 
benefit and the concept of cleaning the blood and returning it to the body has endured since 
almost the beginning of recorded time. Access to the veins was obtained initially by the use of a 
quill and subsequently by various types of needles. These same methods were then applied to the 
arterial circulation. Repeated arterial and venous punctures, however, soon consumed the readily 
available sites. Initially, operations for access were used for a variety of disorders. These 
included blood dyscrasias, chemotherapy, and occasionally chronic hyperalimentation. With the 
development of specifically designed silastic catheters, these indications are now only rarely 
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valid, and these procedures are, in general, limited to the management of renal failure 
(53,57,58,63,92,93). 
 
Since properly functioning vascular access is of the most importance to the patient with renal 
failure, the surgeon must consider many factors in the choice of operative procedures. These 
include the age and gender of the patient, the interval from access placement to planned use, and 
the anesthetic required to construct the chosen access. The decision to dialyze is often deferred 
until the situation becomes urgent. Each shunt or fistula operation must be planned carefully, as 
these patients with chronic renal failure will require a life-long therapy (53,58,88,94). 
 
For emergency hemodialysis access, preferred are femoral vein catheters, which can be 
maintained in place for up to 48 hr. Femoral veins can be used repeatedly for several weeks. If a 
longer, albeit temporary, access is required, double-lumen catheters are used and placed 
percutaneously in the subclavian vein. This allows the patient to be ambulatory and the catheter 
has been well tolerated by the patients treated this way. The catheters are easily placed under 
local anesthetic and can and should be used immediately after placement (56,57,66). 
 
 
1.8.1. Vascular access for hemodialysis 
 
A vascular access is an access created by a connection between an artery and a vein, or 
connection between an artery and a vein with graft, whereby the vein or graft serves as an 
accessible conduit to remove and return blood during hemodialysis (8, NIH Publication No.14-
4554 May 2014). 
 
End-Stage Renal failure patients requiring a long-term hemodialysis need a durable vascular 
access (57,95,96). 
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More than 60% of all patients with ESRD who require chronic hemodialysis are accessed 
through an arteriovenous fistula (AVF) or arteriovenous graft (AVG), and the incidence is 
increasing at a rate of 2% to 4% per year. The goal of chronic vascular access is to provide 
repeated access to the circulation with minimal complications (88,89). 
 
Good vascular access must be easy to prepare, long lasting, free from complications, and 
esthetically acceptable and economical (58,97). 
 
With the increasing number of patients sustained on chronic hemodialysis, access related surgery 
forms a significant portion of vascular surgical practice (95). Performance of a successful 
hemodialysis procedure requires a functional vascular access (98,99). Ferrari et al. defined 
vascular access for dialysis as the “Achilles heel”, but also the “Cinderella” of dialysis, 
indicating the poor consideration of the problem whether in the surgical environment, or in 
incomprehensible way in that nephrologic (97,100). 
 
Arteriovenous fistulas require fewer interventions than grafts to maintain long-term patency for 
dialysis. For this reason, the National Kidney Foundation Dialysis Outcomes Quality Initiative 
guidelines recommend placement of fistulas in preference to grafts whenever the vascular 
anatomy permits it (96,99,101,102). 
 
The three principal forms of chronic vascular access for hemodialysis are native arteriovenous 
fistulas, arteriovenous synthetic grafts, and double-lumen tunneled cuffed catheters. The first two 
types are conduits between the artery and vein, which provide a rapid blood-flow rate (103). Of 
these, the AVF comes the closest to being an ideal long-term hemodialysis vascular access 
(55,58,80,101). 
 
The management of the vascular access must preview one tight collaboration between 
nephrologists, nurses, patient, vascular surgeon, and radiologist (100). 
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1.8.1.1. Acute hemodialysis access 
 
The usage of temporary and permanent dialysis catheters for hemodialysis vascular access has 
been on continual increase (93). In some patients, the only access for hemodialysis is possible 
through a central vein catheter. The first catheter was introduced by Sheldon in 1961 (96). 
 
- Percutaneous non-tunneled catheters intended for temporary access 
 
- Double-lumen tunneled cuffed catheters (tunneled central venous catheter) intended for 
 
prolonged usage 
 
Cuffed versus uncuffed is indicated whether they are equipped with a subcutaneous cuff to 
promote tissue ingrowth and further fixation of the catheter (85). Use of an uncuffed catheter for 
periods of time beyond several weeks results in a relatively high rate of infection and is not 
recommended. Dacron or felt cuffs bonded to the catheter reduce the incidence of line-related 
infection and of catheter migration and must be used whenever a longer-term use of the catheter 
is anticipated, or when it is anticipated that a patient will be discharged from the hospital with a 
catheter remaining in place (53,79,96). 
 
The optimal insertion side is the right internal jugular vein. The subclavian site should generally 
be avoided because it is associated with a higher incidence of insertion-related complications. 
Catheterization of the femoral vein is a good choice when the need for hemodialysis is expected 
to be short (<1 week). It is useful for performing the initial hemodialysis treatment in patients 
who present with acute pulmonary edema, because the patient head and chest can be elevated 
during insertion (66,79,92). 
 
All catheters need to be inserted into hospitalized, bed-ridden patients. 
 
In recent years, the use of tunneled central venous catheters (CVC) has grown exponentially. 
But, their use is not always justified. In comparison with grafts, CVCs have various 
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disadvantages including insertion-related complications, possible malfunctioning, risk of 
infections and thrombosis, but above all a high risk of steno-occlusion of central veins (104,105). 
These should be avoided at all costs, except as a temporary measure or when the life expectancy 
of the patient is short. Unfortunately, this often is difficult to accomplish at a clinical level 
because this is the most convenient way to obtain immediate dialysis access (53,98). Cifarelli et 
al. in their experience consider some conditions in which the use of the CVC is a priority, 
namely in patients with severe cardiopathy and reduced ejection fraction in whom volume 
overload caused by a graft access increases the risk of cardiac failure; in pediatric patients 
weighing less than 20 kg, in whom a graft vascular access could cause notable, even insuperable 
difficulties of construction and management, as well as negative psychological implications for 
the small patient; in very elderly patients in poor clinical condition with a short life expectancy 
or suffering from cancer, in whom a CVC could be used also for the infusion of 
chemotherapeutic drugs; and in patients with peripheral arteriopathy in whom the alternative is a 
graft in a lower limb, because of the high risk of ischemia (88,93,99,104). 
 
Complications that occur at the time of catheter insertion are secondary to inexperience, 
pneumothorax, arterial/venous injury, brachial plexus/phrenic nerve injury, cardiopulmonary 
complications, mechanical failure, thrombosis and infection. Clearly, these issues can be avoided 
when the fistula has been constructed in a timely fashion in pre-dialysis patients, so that it is 
ready for use prior to the need for maintenance dialysis (53,55,57,66,78,105). 
 
Whether arguing the benefits of “Fistula First” or "Catheter Last," the fact that clinicians are in 
need of an alternative to expanded polytetrafluoroethylene (ePTFE) is irrefutable. While the bulk 
of this effort has historically focused on developing new synthetic biomaterials, more recently, 
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investigators have developed a variety of cell-based strategies to create tissue-engineered 
vascular grafts (82,99,106,107). 
 
Every patient should undergo chest radiography after a central catheter is placed. 
 
 
 
 
1.8.1.2. Chronic hemodialysis access 
 
1.8.1.2.1. Arteriovenous fistulas 
 
In 1966, Brescia and colleagues described a technique for creating an arteriovenous fistula based 
upon the radial artery and any available forearm vein. Even today, forty years later, "the Cimino-
Brescia radiocephalic fistula... remains unquestionably the best available form of vascular access 
for hemodialysis because of its unequaled long-term patency rate and minimal complications" 
(84,96,105,108). 
 
The groundbreaking article by Brescia and Cimino in 1966 revolutionized the creation of the 
vascular access, and the Cimino fistula was soon used in almost all dialysis patients 
(55,80,96,109). The surgeon usually places an AV fistula in the forearm or upper arm (Figure 3) 
(69). An arteriovenous fistula is the most preferred form as it is essentially free of infection, 
provides a high blood flowrate, lasts longer than other types of access and is the least likely to 
clot (53,55,78,84,101,105). 
 
Routine preoperative sonographic vascular mapping is recommended before each access surgery 
to assist the surgeon in determining the optimal location for fistula creation (55,58,71,72,78, 
102). 
 
Although several techniques for anastomosis are available, the side-to-end anastomosis has 
deservedly become the most commonly used technique. It is absolutely indicated when artery 
and vein are far apart and must be brought closely together to create an anastomosis. As a further 
 
 
23 
 
advantage, a venous thrombosis will affect only the venous limb if it supervenes. If the fistula 
has to be revised, it is easy to create an anastomosis at a more proximal site. Because the number 
of vascular access sites is limited, the preservation of each site for as long as possible is 
important for the long-term management of these patients (55,78,80,84,88,96,105). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Primary sites of AVF creation adopted from Shenoy (69) 
 
 
 
 
 
The anatomical snuffbox fistula may be the first considered in any patient requiring hemodialysis 
access, because failure still leaves several options for fistula available on that limb (110). 
 
It is well recognized that AVFs, as access for hemodialysis, are less prevalent among patients of 
older age, of female gender, with obesity, diabetes or cardiovascular disease (86,96,111). 
Patients who benefit from preoperative ultrasound evaluation are those with: 
 
- insufficient clinical examination (obese, absent pulses, multiple previous access surgery) 
 
- possible arterial disease (older age, diabetes, cardiovascular disease) 
 
- possible venous disease (previous cannulation) (71,72,73,90,94,111,112). 
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The biology of the AV fistula is fascinating and the adequate management of the fistula and its 
complications should be based on pathophysiologic reasoning (80,109). Complications of AV 
fistula include thrombosis, infection, bleeding, increased venous pressure, arterial insufficiency, 
aneurysm, carpal tunnel syndrome, distal ischemia, and even heart failure. Complications related 
to AV fistula increase with age, because of comorbidities (53,55,73,80,83,94). 
 
- Maturation of fistula 
 
“Maturation” of an AVF involves dilation of the runoff vein, thickening of its wall, and 
eventually enlargement of the afferent artery. Therefore, the quality and diameter of the artery 
plays a major role in the maturation of the AVF (53,57,69). 
 
Banerjee et al. referred to a “rule of sixes” in the fistula assessment. At 6 weeks post-creation, 
the diameter of the body of the fistula should be at least 6mm. The depth should not be more than 
0.5 to 0.6cm. The blood flow rate should be 600ml/min or more by this time. The length of the 
fistula should be 5 to 6cm to allow for a successful two-needle dialysis (103). 
 
Delay in maturation or failure of maturation of Cimino-Brescia fistulas contributes to the 
significant vascular access-related morbidity of chronic hemodialysis patients (109,114). 
 
An AV fistula frequently requires 2 to 3 months to develop or mature, before the patient can use 
it for hemodialysis. A significant number of AVF (28-53%) never mature to support dialysis. 
Often, nephrologists and vascular surgeons wait up for 6 months and even longer hoping that the 
AVF will eventually grow to support dialysis. In general, a blood flow of 500ml/min and a 
diameter of at least 4mm are needed for an AVF to be adequate to support dialysis therapy 
(101,115,116,117). 
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The first step in a systematic evaluation of the mature AVF is to examine the integrity of the skin 
overlying the fistula, which should appear normal without erythema, focal masses, or focal 
swelling (53,82,110,118). 
 
 
1.8.1.2.2. Arteriovenous graft 
 
For more than 30 years, research and industry have attempted to introduce into clinical practice 
solutions and products that could remedy the impossibility to use native veins. AV grafts are 
reserved for patients whose vascular anatomy does not permit construction of a native AV fistula 
(55,104,107). 
 
Vascular grafts of various types have been created that would approach the ideal characteristics 
as closely as possible those are a low antigenic power, high resistance to infections, low risk of 
thrombosis, and easy pierceability but high resistance to puncturing (90,104). 
 
The prostheses nowadays used in the vascular access for hemodialysis have low patency rates, 
due to the luminal obstruction, determined by the intimal hyperplasia (99). An AV graft is more 
likely than an AV fistula to have problems with infection and clotting. Repeated blood clots can 
block the flow of blood through the graft (55,95). 11% to 35% of patients develop infection, 
which represents one of the main causes of access failure (119). In view of their complication 
profile, the native vein arteriovenous fistula should continue to be the first choice for vascular 
access among patients requiring chronic hemodialysis (56,77,95,99). 
 
- Maturation of graft 
 
Although some advocate immediate use of an AV graft for hemodialysis, adhesion between the 
graft and the subcutaneous tunnel to prevent hematoma formation requires at least 2-3 weeks. 
Graft is considered mature when edema and erythema have resolved and the graft can be easily 
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palpated. The graft should be cannulated immediately postoperative only to avoid risks from 
 
temporary catheters (81,97,99,105). 
 
 
 
 
1.8.2. How does a patient care for and protect vascular access? 
 
A patient can care for and protect a vascular access by: 
 
1. Ensuring that the health care provider checks the access for signs of infection or problems 
with blood flow before each hemodialysis treatment, even if the patient is inserting the 
needles. 
 
2. Keeping the access clean at all times. 
 
3. Using the access site only for dialysis. 
 
4. Being careful not to bump or cut the access. 
 
5. Checking the thrill in the access every day. The thrill is a rhythmic vibration a person can 
feel over the vascular access. 
 
6. Watching for and reporting signs of infection, including redness, tenderness, or puss. 
 
7. Not letting anyone put a blood pressure cuff on the access arm. 
 
8. Not wearing jewelry or tight clothes over access site. 
 
9. Not sleeping with the access arm under the head or body. 
 
10. Not lifting heavy objects or putting pressure on the access arm (82,85,116,120). 
 
 
 
 
1.8.3. Failure of arteriovenous fistula 
 
Dysfunction of the AVF is a common problem in hemodialysis patients and remains a major 
cause of morbidity and hospitalization (55,80,119,121). The failure of an AVF may be defined as 
the early or late failure: 
 
 
27 
1. the early failure: inflow and outflow problems; 
 
2. the late failure: venous stenosis, arterial stenosis and thrombosis. 
 
The early fistula failure or a failure to mature fistula is defined as a fistula that has never matured 
to be useful, is difficult to cannulate, or fails to generate necessary blood flow for a successful 
two needle dialysis (103). 
 
Miller et al. showed a higher primary nonfunction rate in forearm fistulas as compared with 
upper arm fistulas (59% versus 34%) (119). 
 
The 1-year patency rates of AVF are estimated to be 63%, and recurrent AVF failure is a major 
cause for morbidity and mortality of hemodialysis patients (55,78,80,82,121). Studies relating to 
preoperative venous mapping for AVF construction underwent systematic review. Doppler 
ultrasound is the preferred method for preoperative vascular mapping. Preoperative vascular 
mapping was shown to substantially increase the total proportion of patients dialyzing with 
fistulas (53,55,71,72,82,101,107,121,122). 
 
The pathogenesis of the early native arteriovenous fistula failure (juxta-anastomotic stenosis) is 
complex and multifactorial. Causative factors include a small artery (<1.5 to 2 mm) and a small 
vein (<2.0 to 2.5 mm), surgical manipulation and less-than-ideal technique, previous 
venipunctures, the development of accessory veins that direct blood away from the primary 
venous drainage channel, hemodynamic stressors, and a possible genetic predisposition to 
vasoconstriction and neointimal hyperplasia after endothelial and smooth muscle injury 
(107,109,119,121,122,123). Roy-Chaudhury et al. in 2006 recognized that all vascular 
manipulations (surgery or balloon angioplasty) cause endothelial and smooth muscle cell injury, 
which results in a restenotic process. Therefore, these interventions need to be linked to therapies 
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that can target both the traditional and the alternative pathways that are involved in the 
pathogenesis of neointimal hyperplasia and vascular stenosis (55,117,119,123). 
 
The possible biologic reasons for an AVF to undergo maturation failure are as follows: 
 
- Failure of the arterial dilation because AVFs are created in patients with severe vascular 
disease and diabetes; 
 
- Failure of the venous dilation because of the aggressive push toward trying to create a 
native AVF whenever possible and it could result in the use of a poor venous segment 
that has lost the ability to vasodilate because of previous venipuncture (80); 
 
- Significant stenosis at the anastomosis, which is the most common anatomic abnormality 
in fistulas that fail to mature (121); 
 
- Accelerated venous neointimal hyperplasia as a result of vascular injury of the segment 
of vein that has been mobilized and manipulated by the surgeon during the procedure. 
This process often involves stretching, torsion and skeletonization of the vessel, which 
may disrupt the vasa vasorum for that segment of the vein. Morphologically, neointimal 
hyperplasia results from proliferation of SMCs combined with matrix deposition 
(54,115). 
 
The chronic kidney disease is associated with vascular damage, and it is likely that uremia may 
impair AVF patency, too (54). 
 
To preserve the vascular system, it is important to avoid blood withdrawals or intravenous 
infusions from the arm and forearm, and to use the veins of the hands for these purposes (108). 
The four main problems identified as associated with occlusion are: (1) low blood pressure 
during hemodialysis; (2) successive fistula puncture sites located too close to one another; (3) 
abnormal blood flow; and (4) poor moisture control. 
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Age is an additional independent factor associated with the prevalence of fistulas. Other factors 
include presence of peripheral vascular disease, obesity and lower socioeconomic status. Allon et 
al. showed that female gender and black race are independent predictors of a lower likelihood of 
fistula placement (55,85,117,123). 
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2. HYPOTHESIS 
 
 
Apoptosis correlates positively with previous venipuncture and failure of AVF. 
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3. AIMS OF STUDY 
 
 
3.1. GENERAL AIM: 
 
 
To investigate the impact of apoptosis in the native vein wall used for arteriovenous fistulas for 
 
hemodialysis on the failure of fistulas. 
 
 
3.2. SPECIFIC AIMS: 
 
1. To evaluate apoptosis in the native vein wall of patients who will undergo a surgery for 
AVF as dialysis access. 
 
2. To compare apoptosis between the veins previously punctured or not. 
 
3. To assess the number of patients with AVF failure and correlate it with apoptosis. 
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4. MATERIALS AND METHODS 
 
4.1. Subjects 
 
Vein specimens were obtained from 60 patients with terminal chronic renal disease, at the Clinic 
of Vascular Surgery in University Clinical Center of Kosovo, who, for first time, underwent a 
surgery for AVF placement as dialysis access. The indication for creation of a vascular access 
was done by a nephrologist, and his staff advised the patient on how long to fast prior to the 
procedure, and which medications to take or not to take. 
 
Patients in whom AVF did not develop to sustain dialysis or was thrombosed before the first 
successful cannulation for hemodialysis, as well patients in whom AVF was made with graft 
prosthesis, were excluded from the study. 
 
Group I (study group) consisted of 30 patients in whom the vein which was used for AVF 
placement had been previously punctured (for blood draws or for intravenous lines), irrespective 
of the purpose of puncture. 
 
Group II (control group) consisted of 30 patients in whom the vein which was used for AVF 
placement had not been previously punctured. 
 
The patients were prepared for surgery, provided their systolic blood pressure would not be less 
than 100 mmHg. Both upper extremities were then examined, and the extremity which had an 
appropriate artery and vein, at preferably the nondominant extremity, was chosen for the 
placement of the fistula. The most distal possible site was chosen for AVF placement. 
 
All patients had a competent deep vein system without a history of thrombotic episodes. 
 
For each patient, the following data were included for analysis: data related to age, gender, time 
of AVF surgery, duration of renal failure, duration on dialysis or the placement of fistula made 
for preventive purposes, site of fistula, type of fistula, Doppler sonographic data before fistula 
 
 
33 
 
placement, presence of comorbid conditions, such as diabetes mellitus, arterial hypertension, 
pulmonary disease, previous cerebrovascular disease, previous peripheral vascular disease, 
rheumatologic disease, cancer, use of ACE inhibitors, statins, calcium antagonist, coumarin, 
platelet aggregation inhibitor, prior central catheter placement, HBs antigen, HCV, HIV, history 
of intravenous drug abuse, and smoking. 
 
All preoperative sonographic mapping studies were performed by a vascular surgeon. A Siemens 
Acuson X300 system with a 7- to 15-MHz transducer was used. The patient was placed in the 
supine position with the arm to be examined comfortably extended at approximately 60 degree 
angle from the chest. The veins were sequentially evaluated along the arm for diameter, patency, 
and depth. Stenosis and thrombosis of the draining or central vein were criteria for exclusion 
from the study. 
 
The conditions of the artery and vein were examined by the surgeon and based on the degree of 
arterial atherosclerosis, blood flow and the presence of thrombosis, they were divided into three 
types: excellent, good and sufficient, as follows: 
 
- Excellent artery: a minimum of 2 mm in internal diameter, a soft and elastic artery wall 
with no atheroma and a good flow; 
 
- Good artery: a minimum of 2 mm in internal diameter, a relatively stiff artery wall but 
with no atheroma and an average to good flow; 
 
- Sufficient artery: a minimum of 2 mm in internal diameter, a hard and fragile artery wall 
with atheroma and an average flow; 
 
- Excellent vein: a minimum of 2 mm in internal diameter, a normal wall, lacking any 
clots and thrombosis, completely open proximal, a good flow, and dilates and fills well 
with pressure on the proximal part of the vein; 
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- Good vein: a minimum of 2 mm in internal diameter, an appropriate wall, lacking 
proximal obstruction, but having proximal stenosis, which could be removed by a dilator. 
The vein will appropriately fill up with blood after release of the proximal pressure; 
 
- Sufficient vein: a minimum of 2 mm in internal diameter, a stiff wall, relative stenosis or 
obstruction of the proximal, in which case a dilator of maximum size-2 will pass through. 
A low flow rate and when controlling the proximal part of the vein, does not fill up 
 
appropriately with blood and will not dilate desirably. 
 
To all patients vascular access was performed on an outpatient basis, under local anesthesia, in 
one or other arm. Radial artery-cephalic vein forearm fistula or brachial artery-cephalic vein 
upper arm fistula were placed, with termino-lateral anastomosis. The vein taken during the 
procedure was always the cephalic vein, and it was 1cm longer than usually taken during the 
operation. Before placement of AVF, 1-cm vein segment was excised from the distal part of the 
vein for immunohistochemical analysis. Then, the vessel was irrigated and dilated with heparin-
saline solution. Afterward, we performed end-to-side arterio-venous anastomosis using 6/0 or 7/0 
polypropylene suture material (Figure 4). 
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Figure 4. Procedures for retrieving vein material. A. Preparation of artery and vein. B. C. Vein 
division. D. Retrieving the venous segment (1cm). E. Radial-cephalic fistula;  
Note: 1. Cephalic vein, 2. Radial artery. 
 
 
 
The fistula maturation took 4-6 weeks or depending on the patient conditions. Until then, patients 
did the dialysis in the central venous catheter, except when AVF was done for preventive 
purposes. 
 
Patients were followed on an outpatient basis after 3, 6, 9 and 12 months and the failure of AVF 
was noted. All patients were dialysed on standard bicarbonate basis for 4h three times weekly 
using biocompatible polysulphone HD membranes (Fresenius). 
 
 
4.2. Tissue preparation 
 
All vein specimens were divided into two portions along longitudinal axis. The specimens 
collected were fixed in 10% buffered solution containing approximately 4% formaldehyde for 
38 
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24h and embedded in paraffin for conventional histology and immunohistochemistry. Tissue 
preparation took place at the Department of Pathology of the University Clinical Center of 
Kosovo, in Prishtina. 
 
Histology and immunohistochemical analysis were made in “Ljudevit Jurak” Department of 
Pathology, University Hospital Center “Sisters of Mercy”, Zagreb, in my presence. 
 
 
4.3. Histology 
 
Specimens were stained with hematoxylin and eosin for routine histological evaluation. Results 
were evaluated by two independent investigators who were blinded to the patient’s clinical 
findings. All vein specimens were stained with Mallory trichrome, Gomori’s and von Gieson’s 
histochemical staining to assess the pathological changes in the amount of collagen connective 
fibers and to differentiate between collagen and smooth muscle fiber as well as the elastin 
network. Histology was performed for confirmation that the sections used for 
immunohistochemical analysis contained the classical findings of veins which were previously 
punctured and those which were not previously punctured. 
 
 
4.4. Immunohistochemistry 
 
Routinely, identification of smooth muscle cells was performed by experienced histopathologist 
using morphological criteria. 
 
For immunohistochemical analysis, the following primary antibodies were used overnight at 4 
 
°C: 
 
- p53 mouse monoclonal antibody (DAKO), dilution 1:50; 
 
- Bcl-2 mouse monoclonal antibody (DAKO), dilution 1:50; 
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- Caspase 3 mouse monoclonal antibody (Abcam), dilution 1:50; 
 
- Bax rabbit polyclonal antibody (DAKO), dilution 1:500. 
 
For indirect streptavidin–biotin–peroxidase method, instructions from the manufacturer (DAKO) 
were followed. Biotin-conjugated secondary antibody was applied in a 1:200 dilution for 1 h at 
room temperature, then a 30-min incubation in Strept–AB complex was done, and for color 
development 3,3′-diaminobenzidine tetrahydrochloride and hematoxylin as a counterstain were 
used. 
 
Qualitative and quantitative evaluation of the immunohistochemical staining was done using a 
computer with image analysis software according to the article by: Filis et al. (48). The 
expression of proteins was evaluated according to a semiquantitative assessment of positive 
cells. Scoring was performed as: no staining, minimal staining (1-3%), moderate staining (>3-
50%), and maximal staining (>50-100%). Cells that stained positive (cytoplasmic and nuclear 
staining) for the examined antibodies in the intima, media, and adventitia were counted at 400× 
magnification and quantified in 10 random fields per section (16). 
 
As positive controls for Bcl-2, caspase 3 and Bax, tonsillar tissues were used, and for p53, breast 
tissues. Negative control was obtained by omitting primary antibody. 
 
4.5. Statistical analysis 
 
Data management and analysis: Chi square test or Fisher Freeman Halton test were used to test 
the differences in proportions of qualitative variables between groups. Normality of quantitative 
variable distributions was tested by Kolmogorov-Smirnov test. Mann Whitney U test was used 
for testing the differences between quantitative variables which did not follow normal 
distribution. The level p<0.05 was considered as the cut-off value for significance. A descriptive 
analysis is presented in tables and figures. 
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4.6. Ethics 
 
The study was conducted according to all currently valid and applied guidelines whose purpose 
is to assure proper conduction and protection of persons included in this research as examinees. 
Ethical approval for the study was obtained from University Clinical Center of Kosovo, in 
 
Prishtina, University Hospital Center “Sisters of Mercy” in Zagreb, and University of Zagreb, 
School of Medicine, Zagreb. 
 
Identity of patients remained confidential and protected. 
 
A freely given, written informed consent was obtained from participants or from witnesses. 
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5. RESULTS 
 
5.1. Clinical characteristics of patients 
 
According to the preoperative physical examination as well as noninvasive imaging findings, 60 
patients on maintenance HD with an AVF as vascular access were found to be appropriate 
candidates for this study. There were 30 patients (18 men, 12 women; median age 63.50 years; 
IQR=23.00 years) in group I (study group), and 30 patients (20 men, 10 women; median age 
63.00 years; IQR=20.25 years) in group 2 (control group). Co-morbid conditions were seen in all 
patients, and included hypertension (26/21) in both groups, hematologic disease (19/17), and 
diabetes (11/11) (Table 1). 
 
There were no statistically significant differences among the patients in the study and control 
group in age, gender, dialysis performed, central venous catheter insertion, HBsAg, HCV, HIV, 
and comorbidities (hypertension, pulmonary disease, hematologic disease, diabetes, peripheral 
vascular disease, cerebrovascular disease, rheumatologic disease, cancer) (Table 1). 
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Table 1. Characteristics of patients (N=60) 
 
  Group I Group II  
  study group control group p Value 
  (N=30) (N=30)  
    
Age (years) Median/IQR 63.50 63.00 0.695** 
Gender (male/female) 18/12 20/10 0.592* 
No dialysis 11 10 0.787* 
Central venous catheter   0.713* 
- Internal jugular vein 6 9  
- Femoral vein 11 8  
- Subclavian vein 2 3  
HBsAg positive 2 2 1.000* 
HCV positive 1 2 1.000* 
HIV positive 0 0  
Comorbidities    
- Hypertension 26 21 0.117* 
- Pulmonary disease 3 3 1.000* 
- Hematologic disease 19 17 0.598* 
- Diabetes 11 11 1.000* 
- Peripheral vascular disease 2 2 1.000* 
- Cerebrovascular disease 4 0 0.112* 
- Rheumatologic disease 2 1 1.000* 
- Cancer 2 5 0.424* 
 
*-Fischer’s Exact Test, **-Mann-Whitney U Test 
 
 
 
The greatest number of fistulas was observed in the non-dominant extremity, 52 fistulas (86.7%) 
of the total number of 60, the finding in line with the data from literature. There were 35 
(58.33%) radiocephalic fistulas and 25 (41.67%) brachiocephalic fistulas, with no significant 
difference between the two groups (Table 2, Figure 5). 
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Table 2. Intraoperative characteristics (N=60) 
 
  Group I Group II  
  study group control group p Value 
  (N=30) (N=30)  
    
Choice of access site   0.254 
- non dominant extremity 24 28  
- dominant extremity 6 2  
Type of fistula   0.892 
- R/C sin* 15 15  
- B/C sin* 10 12  
- R/C dex* 3 2  
- B/C dex* 2 1  
Condition of artery   0.689 
- sufficient 1 2  
- good 16 18  
- excellent 13 10  
Condition of vein   1.000 
- sufficient 3 3  
- good 13 13  
- excellent 14 14  
 
*- R/C-radiocephalic fistula, B/C- brachiocephalic fistula, p-Fischer’s Exact Test 
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Figure 5. Type of fistula performed in both groups.  
Note. R/C-radiocephalic; B/C-brachiocephalic 
 
 
5.2. Histology 
 
Routine hematoxylin and eosin staining showed histological appearance of the specimens of 
nonpunctured vein (control vein) (Figures 6 and 7), and punctured vein (study vein) (Figure 8). 
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Figure 6. The control vein. The intima (endothelium) (arrow); media (one star); adventitia (two 
stars). HE, x100. 
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Figure 7. The control vein. The arrow points to the intima of vein. HE, x40. 
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Figure 8. The punctured vein. The arrow points to the intima (endothelium); one star denotes 
media; two stars denote adventitia. HE, x200. 
 
 
 
 
 
Mallory and Gomori’s histochemical staining demonstrated a loss of their elongated morphology 
 
in punctured veins and slightly increased collagen matrix with degradation of elastic fibers on 
 
von Gieson’s elastic staining (Figure 9), as compared with non-punctured veins (Figure 10). 
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Figure 9. The punctured vein. A. Mallory trichrome staining; B. Gomori’s staining; C. von 
Gieson’s staining 
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Figure 10. The control vein. A. Mallory trichrome staining; B. Gomori’s staining; C. von 
Gieson’s staining 
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5.3. Expression of apoptotic and antiapoptotic markers (IHC) 
 
5.3.1. Immunohistochemical results in the study group 
 
p53 showed no expression or a minimal expression in veins. Bcl-2 showed a minimal and 
moderate expression. Caspase 3 showed minimal, moderate and maximal expression and Bax 
showed no expression or minimal and moderate expression (Table 3, Figures 11, 12, 13, 14). 
 
 
Table 3. Semiquantitative analyses of markers expression in study group 
 
  p53 Bcl-2 caspase 3 Bax 
      
- 0% 18 0 0 11 
- 1-3%* 12 20 6 14 
- >3-50%* 0 10 18 5 
- >50%* 0 0 6 0 
Total 30 30 30 30 
 
*-minimal staining (1-3% positive cells), moderate staining (>3-50% positive cells), maximal staining (>50-100% 
positive cells) 
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Figure 11. Expression of apoptotic and antiapoptotic markers for the study group  
Note: minimal staining (1-3% positive cells), moderate staining (>3-50% positive cells), maximal 
staining (>50-100% positive cells) 
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Figure 12. Positive cytoplasmic immunohistochemical staining of Bax in the media and intima of 
the punctured vein. IHC, DAB, counterstained by hematoxylin, x200. White arrow points to the 
intima; one star denotes media; two stars denote adventitia; small black arrows point to the 
positive cytoplasmic staining 
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Figure 13. Positive cytoplasmic immunohistochemical staining of caspase 3 in the media and 
intima of the punctured vein. IHC, DAB counterstained by hematoxylin, x400. The arrow points 
to the positive cytoplasmic staining. 
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Figure 14. Positive nuclear immunohistochemical staining of p53 in the media of punctured 
vein,IHC, DAB, counterstained by hematoxylin, x400. The arrow points to the positive nuclear 
staining. 
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5.3.2. Immunohistochemical results in the control group 
 
p53 showed no or a minimal expression in veins. Bcl-2 showed a minimal, moderate and 
maximal expression. Caspase 3 showed no or minimal expression and Bax showed no or 
minimal expression (Table 4, Figures 15,16,17,18). 
 
 
Table 4. Semiquantitative analyses of markers expression in control group 
 
  p53 Bcl-2 caspase 3 Bax 
      
- 0% 19 0 19 23 
- 1-3%* 11 3 11 7 
- >3-50%* 0 20 0 0 
- >50%* 0 7 0 0 
Total 30 30 30 30 
 
*-minimal staining (1-3% positive cells), moderate staining (>3-50% positive cells), maximal staining (>50-100% 
positive cells) 
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Figure 15. Expression of apoptotic and antiapoptotic markers for the control group  
Note minimal staining (1-3% positive cells), moderate staining (>3-50% positive cells), maximal staining 
(>50-100% positive cells). 
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Figure 16. Nuclear immunohistochemical positivity of Bcl-2 in the media of the control vein. 
IHC, DAB, counterstained by hematoxylin, x400. The arrow points to the positive reaction, 
visible as a dark staining in nucleus (black arrow) 
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Figure 17. Positive cytoplasmic immunohistochemical staining of caspase 3 in media and intima 
of the control vein. IHC, DAB, counterstained by hematoxylin, x400. White arrow shows intima; 
black arrows show positive cytoplasmic staining; star shows media. 
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Figure 18. Positive cytoplasmic immunohistochemical staining of caspase 3 in media and intima 
of the control vein. IHC, DAB, counterstained with hematoxylin, x400. White arrow points to 
the intima; black arrows show positive cytoplasmic staining; star denotes media. 
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5.3.3. Comparison of immunohistochemical results between groups 
 
There were significant differences between the two groups for the expression of Bcl-2, caspase 3 
and Bax. Caspase 3 and Bax expression in the study group was increased compared with the 
control group (p<0.01 for all). Bcl-2 expression in the study group was decreased compared with 
the control group (p<0.01). p53 showed no significant differences between the two groups 
(p=0.791) (Table 5, Figures 19,20,21,22). 
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Table 5. Comparison of the apoptotic and antiapoptotic markers expression between the study 
group and control group 
 
 Study group Control group p Value 
    
p53   0.791* 
no staining 18 19  
minimal staining 12 11  
moderate staining 0 0  
maximal staining 0 0  
    
Bcl-2   <0.001* 
no staining 0 0  
minimal staining 20 3  
moderate staining 10 20  
maximal staining 0 7  
    
caspase 3   <0.001* 
no staining 0 19  
minimal staining 6 11  
moderate staining 18 0  
maximal staining 6 0  
    
Bax   <0.002* 
no staining 11 23  
minimal staining 14 7  
moderate staining 5 0  
maximal staining 0 0  
 
*Fischer’s Exact Test  
Note minimal staining (1-3% positive cells), moderate staining (>3-50% positive cells), maximal staining 
(>50-100% positive cells) 
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Figure 19. Expression of p53 (IHC staining)  
Note minimal staining (1-3% positive cells), moderate staining (>3-50% positive cells), maximal staining 
(>50-100% positive cells) 
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Figure 20. Expression of Bcl-2 (IHC staining)  
Note minimal staining (1-3% positive cells), moderate staining (>3-50% positive cells), maximal staining 
(>50-100% positive cells) 
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Figure 21. Expression of caspase 3 (IHC staining)  
Note minimal staining (1-3% positive cells), moderate staining (>3-50% positive cells), maximal staining 
(>50-100% positive cells) 
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Figure 22. Expression of Bax (IHC staining)  
Note minimal staining (1-3% positive cells), moderate staining (>3-50% positive cells), maximal staining 
(>50-100% positive cells) 
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5.4. Clinical characteristics of patients after the one-year follow-up 
 
During the one-year follow-up, fistula failure occurred in eight patients of the study group, and 
in two patients of the control group. Five patients with a functional fistula in the study group and 
three patients in the control group were lost during follow-up (Table 6). 
 
 
Table 6. Clinical characteristics during one-year follow-up 
 
 Group I Group II Total 
    
 Death 5 3 8 
    
 Fistula failure 8 2 10 
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There were statistically significant differences in fistula failure between the study group and 
control group (26.7% versus 6.7%, p=0.038) (Table 7, Figure 23). 
 
Table 7. Fistula failure within study group (Group I) and control group (Group II) 
 
   Group I Group II Total 
   study group control group  
 NO Number 22 28 50 
  % within fistula failure 44.0% 56.00% 100% 
  % within group 73.3% 93.3% 83.3% 
  % of total 36.7% 46.7% 83.3% 
FISTULA      
FAILURE      
 YES Number 8 2 10 
  % within fistula failure 80.0% 20.0% 100% 
  % within group 26.7% 6.7% 16.7% 
  % of total 13.3% 3.3% 16.7% 
      
  Number 30 30 60 
Total % within fistula failure 50.0% 50.0% 100% 
  % within group 100% 100% 100% 
  % of total 50.0% 50.0% 100% 
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Figure 23. Comparison of fistula failure between the study group and control group 
 
 
 
 
There was also a direct correlation between p53 and central vein catheter, which means patients 
who were performing dialysis by CVC, before fistula placement. Statistically significant 
differences were found in correlation with two groups together, p=0.011, and in correlation with 
the control group, p=0.015. But, there was no statistically significant difference in correlation 
with the study group, p=0.266. 
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6. DISCUSSION 
 
6.1. Clinical procedures and patients characteristics 
 
Nowadays, the number of patients with end stage kidney disease is continuously growing. When 
performing the vascular access, the surgeon must know that nothing less than perfection is 
acceptable (52,53,92,96). 
 
Considering the fact that no research has been done yet on the veins of the upper extremities, the 
only way to achieve results was to study the veins which are used for hemodialysis access. Our 
interest was to investigate the apoptosis of these veins. 
 
To our knowledge, no published studies have before evaluated apoptosis of veins in upper 
extremities, or in patients who will undergo a surgery for arteriovenous fistulas for hemodialysis 
access (13,31,39,124). 
 
Cell death is important for both development and tissue homeostasis in the adult. Abnormalities 
in the control of cell death contribute to a variety of diseases such as atherosclerosis, aneurysm 
formation, ischemic cardiomyopathies, infarction, varicose veins, tumors, etc. (125,126,127). 
Numerous studies have reported on apoptosis in atherosclerotic plaque, varicose vein, occluded 
saphenous vein graft, myocytes, etc. (14,38,124,128). 
 
Increased levels of VSMC apoptosis are seen in mature atherosclerotic plaques compared with 
control vessels, and in unstable angina compared with stable angina (39,124). Previously, several 
studies have reported on apoptosis of varicose veins of the lower extremities 
(25,26,30,31,46,48,125,126,129,130). 
 
As our Clinic is a reference center in the region, we place all arteriovenous accesses for 
hemodialysis. We ourselves perform the arterial and venous Doppler US. 
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There are still some difficulties in managing vascular access, creating it and dealing with all of 
its complications. With patients with serious access problems, there is a need to determine the 
patency of arteries and central veins by arteriography or venography. Reducing factors that 
aggravate stenosis will lead to a reduced rate of fistula failure (77,80,81,94,96,116). 
 
Our research was conducted on patients who for the first time had arteriovenous fistula placed 
for hemodialysis access. The same patients were followed over a year, to assess the function of 
that fistula. 
 
In the present study, the median age of group 1 was 63.50 years, and the male/female distribution 
was 18/12. This did not differ from group II, which involved patients with median age 63.00 
years, and with a male to female ratio of 20/10. The study of Simovart et al. revealed that in 
varicose veins ECs and SMCs apoptosis increased with advancing age. Urbanek et al. described 
an increase of the apoptotic index in the media of varicose veins of patients younger than 50 
years, but not in the older age patients (30,46,51,124). 
 
When dealing with the issue of vascular access in diabetic patients, late referral has a special 
impact on diabetes, since it is common opinion that dialysis should be started earlier in these 
patients. We could not detect any significant difference between the groups, as to diabetes as a 
comorbidity. All our patients were on insulin therapy, which is in agreement with the fact of late 
referral. Therefore, practitioners must be alerted as to their key role in referring diabetic patients 
with nephropathy to the nephrologist on time. Venous sparing, starting from the very beginning 
of renal failure, is another rule, to be strictly adhered to by health professionals: very often 
forearm veins are repeatedly cannulated for infusions and blood drawings in candidates for 
hemodialysis (69,73,76,100,105,123). Sedlacek et al. observed similar maturation rates of 
fistulas among diabetic and non-diabetic patients (55,94). 
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Also in terms of other associated diseases, such as hypertension, hematologic disease, 
cerebrovascular, pulmonary, rheumatologic disease and cancer, we did not observe statistical 
difference as compared between the two groups. 
 
Chronic hemodialysis patients are at high risk of infection because the process of hemodialysis 
requires vascular access for prolonged periods. In an environment where multiple patients 
receive dialysis, repeated opportunities exist for transmission of infection, either through person-
to-person, directly or indirectly via contaminated devices, equipment, environmental surfaces, or 
hands of personnel (84,105,109,131). In our study, we observed a very small number of patients 
with positive HBsAg (two patients in group I; two patients in group 2), and positive HCV (one 
patient in group 1; two patients in group II). Meanwhile no patient was HIV positive. It also 
confirms the fact that patients in our research just started or were still not on dialysis, because the 
study included only those patients who for the first time had arteriovenous fistula placed. In our 
study, there were 19 patients in group I, and 20 patients in group II, who at the time of entering 
the study were undergoing hemodialysis through the central vein catheter. We did not find 
statistically significant differences between the groups in the number of placed catheters and the 
vein in which the catheter was placed. Smaller number of cases had catheter placed in the 
subclavian vein (two patients out of 19 with CVC, in group I; three patients out of 19 with CVC, 
in group II). This is consistent with the data from the literature, to place CVC in the subclavian 
vein as little as possible, in order that a possible subclavian vein thrombosis could compromise 
fistula placed in that area. Duplex ultrasonography assessment of veins is frequently used before 
a hemodialysis arteriovenous fistula placement. Accurate determination of venous diameter is 
important, because this parameter has been demonstrated to correlate with long term AVF 
patency. Smith et al. showed that the present guidelines suggest a minimum diameter of 2 mm 
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for a radial artery, and a minimum diameter of 2 mm for a cephalic vein for successful AVF 
placement at the wrist. These measures have been evidenced by meta-analysis demonstrating 
significant differences in fistula success rates between diameters >2.0 and <2.0 mm 
(70,86,94,101,122,132). A previous study found that the only parameter that affects maturation 
time of brachiobasilic fistula is the vein diameter. AV fistulas using basilic veins with diameters 
larger than 3mm could be used for hemodialysis in the short term (90,103,118). 
 
Van der Veer et al. showed that less than half of the patients were estimated to receive routine 
diagnostic imaging of the vessel prior to access creation. As potential reasons they suggested 
skepticism among vascular surgeons regarding the benefits of imaging, limited access to 
equipment and expertise, and lack of reimbursement. On the other hand, some other reports 
observed that while using preoperative physical examination alone, only a small proportion of 
patients (0 to 34%) received a fistula, rather than a graft. Following the introduction of routine 
preoperative vascular mapping, the proportion of patients receiving fistulas increased to 63 to 
100% (55,78,133). Vessel diameters in our study were generally well above the widely 
recommended minimum artery and vein diameters of 2.0 and 2.5 mm, respectively. Neither 
group had surgical complications or thrombosis in the immediate postoperative period. In the 
present study, we estimated the condition of artery and vein, pre- and intraoperative, and we did 
not find a significant difference in results obtained from the comparison between the two groups. 
 
6.2. Apoptosis in blood vessels 
 
Previous studies of apoptosis in blood vessels often were opposed to each other. Isner et al. 
performed immunohistochemical staining studies on specimens retrieved from patients 
undergoing directional atherectomy for primary atherosclerotic lesions or recurrent arterial 
narrowing after percutaneous revascularization or restenosis. They documented that specimens 
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retrieved from patients with restenosis were more frequently observed to contain foci of 
apoptosis than were specimens retrieved from patients with primary atherosclerotic lesions 
(40,43). Ducasse et al, studied a group of patients who had previously undergone varicose vein 
surgery, which preserved the saphenous trunk. Findings in that group were identical to those in 
patients with primary varices. They suggested that the abnormal apoptosis is irreversible once it 
affects the venous system (26,125). Furthermore, a previous study concluded that the apoptosis 
of ECs and SMCs in the walls of varicose veins maybe differently regulated or these cells react 
differently to apoptotic stimuli (51). Apoptosis has been verified in various cardiovascular 
diseases, such as arrhythmogenic right ventricular dysplasia, acute myocardial infarction, and 
congestive heart failure (14,124,128,134). 
 
Recent studies on apoptosis in the cardiovascular system stem from the hope that understanding 
the mechanism of apoptosis in cardiac myocytes may provide new strategies to prevent myocyte 
loss at major cardiac disease states such as ischemic heart disease and congestive heart failure 
(19,135). Apoptosis due to immune mechanism could be a major cause of myocarditis. During 
cardiac surgery with cardiopulmonary bypass, mechanical stress and hypothermia induce 
myocardial apoptosis, too (14). Deblois et al. proposed that cardiovascular hyperplasia may be 
reversed via therapeutic apoptosis induction with drugs that are safe and already used in the 
clinic (124,134). Also, Kovačević et al. concluded that if the apoptotic cell death significantly 
contributes to the expansion and rupture of abdominal aortic aneurysm, the hypothesis is that 
aggressive medical antiapoptotic treatment with high doses of appropriate drugs could decrease 
the apoptotic index of smooth muscle cells, reduce the aneurysm expansion and prevent rupture 
(38). Furthermore, occlusion of saphenous vein grafts is a major problem after coronary artery 
bypass grafting. Previous studies showed that vein graft disease, an accelerated form of 
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atherosclerosis, shares etiologic mechanisms with restenosis after angioplasty. Their data could 
open new therapeutic strategies with the goal of improving SMC survival, and hence increasing 
plaque stability and reducing vein graft occlusion rates (42,136). Most histopathological studies 
describe intimal hyperplasia and accelerated atherosclerosis in the vein grafts as the reason for 
occlusion (136). Recent studies suggest that in the cardiovascular setting, apoptosis is one of the 
many processes controlled by statins, because they are thought to stabilize plaques and help 
prevent the development of acute coronary syndromes triggered by plaque disruption. Plaque 
breakdown and rupture seem to be related to SMC apoptosis (38,42,124). 
 
There is no totally specific apoptotic marker that solely detects apoptotic cells, so that a 
combination of techniques should always be used to detect apoptosis. The TUNEL staining 
method is now the most widely used marker for apoptosis in cardiomyocytes. A weakness of this 
method is that DNA fragmentation is not 100% specific for the apoptotic type of cell death 
(5,20,42). In many published myocardial sections with positive TUNEL staining, apoptotic cells 
and nuclei exhibit a strikingly normal morphology and only few reports provide evidence for 
ultrastructural alterations such as chromatin condensation, nuclear fragmentation, formation of 
apoptotic bodies and phagocytosis of cell remnants (135). All these facts increased doubts that 
evidence for apoptosis solely based on TUNEL staining and even DNA laddering may not 
suffice to prove apoptotic cell death. DNA damage is not a unique feature of apoptosis, but can 
occur in necrosis, during repair of reversibly damaged DNA and postmortem autolysis (23,42). 
Previous studies for immunohistochemical analysis of apoptosis in varicose veins and 
thrombosed venous grafts, except TUNEL method, used to localize the expression of Bax, 
caspase 3, caspase 8, caspase 9, Bcl-2, Bcl-xs, Bcl-6, Ki-67, p53, DNA laddering, Annexin V, 
Elisa, Western blot (5,26,30,42,48,129,130). 
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In this study, we selected measurement of Bax as a promoter of apoptosis, Bcl-2 as an 
antiapoptotic marker, caspase 3 as a part of execution phase of apoptosis, and p53 to evaluate its 
role in apoptosis of the veins of the upper extremities. 
 
The process was seen in the different layers of the vein wall with the most prominent 
manifestation in the media of the cephalic vein used for AVF. 
 
Bax expresses proapoptotic activity, and in this study it was significantly increased, in the group 
of previously punctured veins. Our results are compatible in part with those of Urbanek at al., 
which showed increased Bax in the distal part of the varicose vein, but are opposite to the 
findings of Ascher et al., that immunoreactivity for Bax is significantly higher in the normal 
veins (30,129,137). They showed total absence of immmunopositivity for Bax in the adventitia 
of all varicose vein specimens. This is in contrast to findings in the media and intima. The entry 
of SMCs into the apoptotic pathway is regulated by Bax, which is downregulated in varicose 
veins in comparison with healthy veins (125,129). In the study of Ducasse et al., varicose veins 
contained fewer Bax positive cells than healthy veins (26,125). By contrast, in the study of Filis 
et al, one of the main results was increase of Bax expression in varicose veins compared with 
normal veins (48). Also, Simovart et al. showed lower levels of Bax in the intima and media of 
varicose veins of patients over 50 years of age, which could be explained by shifts in the 
sensitivity of cells to apoptosis caused by aging, or by changed signaling during the advanced 
stage of the pathology (51). Hayakawa et al. have reported that expression of Bax protein was 
increased according to the progression of atherosclerosis, whereas expression of Bcl-2 was not 
observed. Discrepancy exists in the literature concerning the expression of Bcl-2 in human 
medial SMC (2). 
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Our results are compatible with the findings by Isner et al, regarding immunohistochemical 
evidence of the Bcl-2 protein. Bcl-2 was identified in sections of nonpunctured veins, with 
significant difference (p<0.001), when compared with previously punctured veins. This finding 
is similar to the study of Isner et al. in control sections of normal vascular tissues excised 
intraoperatively, including internal mammary artery and saphenous vein (43). Some investigators 
reported a lack of immunopositivity for Bcl-2 in atherosclerotic lesions of primary and restenotic 
types (43,137). 
 
Filis et al., as well as Ascher et al., could not detect Bcl-2 expression in varicose veins and 
concluded that this is maybe due to the lack of specificity of the antibody used to cell types in the 
vein tissue. Ascher et al. showed that programmed cell death is inhibited in varicose veins 
(48,129,137). Ducasse et al. found no significant difference for Bcl-2 proteins in patients with 
varicose veins and controls (26,125). 
 
The tumor suppressor p53 has been shown to induce apoptosis when overexpressed in some 
cultured cells (42,48). Traditionally, p53 has been described as a nuclear protein, some recent 
studies indicate a new role for p53 in the cytoplasm and specifically at the mitochondria. 
Hammond et al. found that p53 overexpression is as a response to hypoxia. Based on their data, 
Filis et al. did p53 examination in their study for apoptosis in varicose veins, in order to 
investigate a possible link between low oxygen tension, which was observed in varicose vein 
disease, and p53 overexpression as a response to hypoxia (48,138). We do not have data for 
hypoxia at veins after venipuncture. This problem remains to be further explored in the future. 
 
In the present study, we could not detect any p53 immunopositivity difference between groups I 
and II. However, a previous study observed that immunopositivity for p53 was in fact recognized 
in a subset of restenotic lesions including those with apoptosis. It was identified in atherectomy 
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specimens retrieved from restenotic but not primary lesions (43,124). In the study of Bartels et 
al., the proto-oncogene p53 was exclusively detected in occluded vein grafts (42). Filis et al. in 
their study on apoptosis in varicose veins found expression of p53 only in the tributary and the 
distal GSV of control group that consisted of patients with healthy GSV, used for bypass grafting 
in open heart surgery. Also, Urbanek at al. found increased p53 expression in the distal GSV in 
young patients. They suggested that elderly patients show increased structural vein wall changes, 
and hence, p53 expression is not evident (30,48). Jacob et al. in their study indicate increased 
expression of p53 in the nuclei of vascular smooth muscle cells in the media of injured rat 
carotid arteries, compared with the controls (139). 
 
Earlier studies have demonstrated that activation and cleavage of specific cellular polypeptides, 
termed caspases, play critical roles in the initiation and execution of apoptosis 
(13,23,35,46,48,124). In this study, we observed enhanced caspase 3 expression in group I 
compared with group II, with statistically significant difference (p<0.001). Filis et al. observed a 
significant difference in caspase 3 immunopositivity between varicose vein group and control 
group. It suggests an active apoptotic state in varicose veins (48). 
 
6.3. Fistula failure 
 
Smith et al. showed that AVF placement before dialysis is initiated may allow maturation in a 
biochemical environment preferable to that present once dialysis has commenced. Uremia and 
dialysis itself are associated with increased level of oxidative stress, precipitating endothelial 
dysfunction, neointimal hyperplasia and AVF stenosis. Samples of brachial vein obtained during 
access placement in 15 uremic patients showed significantly greater intimal and medial widths in 
patients who had received >6 months of dialysis compared with those who had received <6 
months of treatment (86). 
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The inflammatory environment in HD patients has been attributed to the incomplete removal of 
uremic toxins that promote inflammatory reactions but also to the HD procedure itself. 
Atamaniuk et al. found that cfDNA released from blood cells by ongoing apoptosis is abundantly 
present in the plasma of HD patients. They showed that the plasma of HD patients mimicked the 
capacity of cfDNA to induce IL-6 in human monocytes indicating that this process may 
contribute to the proinflammatory environment observed in HD patients (3,60,65). 
 
Neointimal hyperplasia and impaired dilatation are important contributors to arteriovenous 
fistula failure. Vein dilation after arterializations is a part of a physiological AVF maturation 
process, which makes recurrent cannulation for dialysis possible. Neointimal hyperplasia results 
from proliferation of smooth muscle cells combined with matrix deposition. There is evidence 
that surgical trauma and modified hemodynamics are associated with endothelial and SMC 
damage (40,41,91,103,119). That was the reason why we took a sample of vein, very carefully, 
without previous dilatation. Langer et al. in their study presumed that it was the uremic 
environment rather than indirect effects that caused the exacerbation of neointimal hyperplasia 
and calcification within the AVF (45). 
 
In the present study, we observed a significant difference in caspase 3 and Bax immunopositivity 
between group I and group II. This finding suggests an active apoptotic state in previously 
punctured veins. And, as a result of this increased apoptotic activity, we think that it comes to the 
biggest failure of fistulas in patients with previously punctured native veins (26.7% vs 6.7%) 
with a significant difference (p=0.038). However, even with that finding, we cannot conclude 
that apoptosis is the main cause of fistula failure. Our results support the hypothesis that 
apoptosis may correlate positively with previous venipuncture and failure of arteriovenous 
fistula. Limitations of our study are the small number of patients. 
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The association we have found between previously punctured veins and apoptosis, indicates the 
role that venipuncture plays in the development of apoptosis, but it does not indicate the role that 
apoptosis itself plays in the failure of AFV, after their puncture for hemodialysis. Further 
research is required to investigate this point. 
 
Also, we found a direct correlation between p53 and CVC, meaning patients who were 
performing dialysis by CVC, before fistula placement. Statistically significant differences were 
found in correlation with two groups together, p=0.011, and in correlation with the control group, 
p=0.015. But, there was no statistically significant difference in correlation with the study group, 
p=0.266. Since our sample was small, this remains to be further explored. 
 
We are in the midst of fundamental changes in the way we address the clinical problem of 
hemodialysis vascular access dysfunction. The purpose of this last section is both to summarize 
where we stand and to make suggestions for future scientific advances in this field (119). 
 
In the future, we are interested to continue the study on thrombosed AVF, considering that 
maybe an acute thrombotic event in the early postoperative phase forms the basis for a total and 
irreversible vein occlusion. Furthermore, it will be very interesting to research if long time 
uremia, and hypotension during or after hemodialysis, is one of the reasons for thrombosed AV 
fistulas. This will also help to define potential targets for future intervention. 
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7. CONCLUSIONS 
 
 
 We did not observe any significant differences between the study group and control 
group, in age, sex, and comorbidities, before AVF placement.

 This study provides evidence that previously punctured native veins used for 
hemodialysis access exhibit increased apoptotic activity, by means of increased caspase 3 
and Bax, compared with nonpunctured veins.

 We found a significant decrease of Bcl-2, as an antiapoptotic marker, in the study group, 
compared with the control group.

 Our results were not supportive of increased p53 expression in the study group compared 
with the control group.

 This study found a significant difference of p53 between patients who were on dialysis 
before AVF placement, who were on hemodialysis through central vein catheter, and 
patients who were not on dialysis before fistula placement, in both groups. A significant 
difference was found in both groups together and separately in the control group, but not 
separately in the study group. This is a very useful piece of information, to investigate 
further research in this point.

 The positive apoptotic findings were not related to patient’s age, sex, or comorbidities.

 Patients with increased apoptosis showed increased fistula failure, suggesting an 
association between apoptosis and fistula failure.

 The association we found between apoptosis and fistula failure, indicates the role that 
apoptosis plays in the function of fistula.
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  Our results suggest that apoptosis may play a role in fistula failure, but we cannot 
conclude that apoptosis is the main cause of fistula failure. Further research is required to 
investigate this point.
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8. SAŽETAK (ABSTRACT IN CROATIAN) 
 
 
APOPTOZA U STIJENCI NATIVNE VENE U NEUSPJEHU ARTERIOVENSKIH 
 
FISTULA ZA HEMODIJALIZU 
 
 
U skladu sa rastućim interesom za proučavanje apoptoze u krvnim žilama, ovo istraživanje je 
jedno od prvih koje procjenjuje apoptozu u nativnim venama namijenjenim za arteriovenske 
fistule (AVF) u hemodijalizi. Cilj ovog istraživanja bio je procijeniti apoptozu u prethodno 
probušenim nativnim venama (istraživana skupina) u usporedbi s neprobušenim nativnim 
venama (kontrolna skupina) u bolesnika koji su podvrgnuti kirurškom postupku za AVF kao 
pristupu za dijalizu. Uzorci cefalične vene dobiveni su od 60 bolesnika prije postavljanja AVF. 
Polovica uzoraka bila je iz prethodno probušenih, a polovica iz neprobušenih vena. Iz distalnog 
dijela cefalične vene izrezan je dio duljine 1-cm, podijeljen u dva dijela duž uzdužne osi i 
pripremljen za imunohistokemijsku analizu. Imunohistokemijska metoda i kvantifikacija signala 
se koristila za procjenu proteinske ekspresije Bax, p53, kaspaze 3 i Bcl-2. 
 
Uzorci vena iz istraživane skupine s prethodno probušenim venama pokazali su značajno 
povećani izražaj kaspaze 3 i Bax u usporedbi s kontrolnom skupinom (p <0.01). Izražaj Bcl-2 u 
istraživanoj skupini bio je značajno smanjen u odnosu na kontrolnu skupinu (p <0,01). Izražaj 
p53 nije pokazao značajnu razliku između dviju skupina (p = 0,791). Otkrivena je statistički 
značajna razlika u neuspjehu fistule između istraživane i kontrolne skupine (26,7% u odnosu na 
6,7%, p = 0,038). Veza koju smo otkrili između prethodno probušene vene i apoptoze ukazuje 
na ulogu venepunkcije u razvoju apoptoze. Bolesnici s povećanom apoptozom u cefaličnoj veni 
pokazali su povećan neuspjeh fistule, pa je to saznanje od značaja za poboljšanje postupka 
izvedbe AVF. 
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9. ABSTRACT 
 
In line with the growing interest for studying apoptosis in blood vessels, this study is one of the 
first to assess the apoptosis in native veins used for arteriovenous fistulas (AVF) done for 
hemodialysis. The aim of this study was to evaluate apoptosis in previously punctured native 
veins (study groupy) compared with not punctured native veins (controls) in patients who 
undergo a surgical procedure for AVF as dialysis access. Cephalic vein specimens were obtained 
from 60 patients before the placement of AVF. Half of the specimens were from the previously 
punctured and half from non-punctured veins. A 1-cm long segment was excised from distal part 
of the cephalic vein, divided into two portions along longitudinal axis and prepared for 
immunohistochemical analysis. Immunohistochemical assessment and quantification of signals 
was used to evaluate the expression of Bax, p53, caspase 3 and Bcl-2. 
 
Vein specimens from the study group with previously punctured veins showed significantly 
increased caspase 3 and Bax expression, compared with the control group (p<0.01). Bcl-2 
expression in the study group was significantly decreased compared with the control group 
(p<0.01). p53 showed no significant differences between the two groups (p=0.791). There were 
statistically significant differences in fistula failure between the study group and control group 
(26.7% versus 6.7%, p=0.038). The association we have found between previously punctured 
veins and apoptosis indicates the role that venipuncture may play in the development of 
apoptosis. Patients with increased apoptosis showed an increased fistula failure, which is of 
importance for the improvement of the AVF procedure itself. 
 
Keywords: native vein, apoptosis, venipuncture, hemodialysis, arteriovenous fistula, fistula 
 
failure 
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